Results 11 to 20 of about 199,785 (356)

Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine [PDF]

The Journal of Clinical Investigation
Although virus-like particle (VLP) vaccines were shown to be effective against several viruses, their advantage over vaccines that include envelope protein only is not completely clear, particularly for mRNA-encoded VLPs.
Chandru Subramani, Michelle Meyer, Matthew A. Hyde, Margaret E. Comeaux, Haiping Hao, James E. Crowe Jr., Vsevolod L. Popov, Harshwardhan Thaker, Sunny Himansu, Andrea Carfi, Alexander Bukreyev   +10 more
doaj   +2 more sources

Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2 [PDF]

npj Vaccines
The COVID-19 pandemic spurred mRNA vaccine innovation, but new SARS-CoV-2 variants highlight the need for vaccines with improved potency and durability.
Jason P. Laliberte, Yingyun Cai, Tara Kenny, Yi Zhang, Kuishu Ren, Kim Rosenthal, Daniel Flores, Richard Roque, Oliver Acton, Vanessa Cadevilla Peano, Noel Janney, Vinita Puri, Sarah Siddiqui, Angela Pack, Giune Padilla, Seme Diallo, Hibret Adissu, Rakesh Choudhary, Hawley Pruitt, Yi-Han Cheng, George Thom, Michael Newton, Cheyne Kurokawa, Johnathan Guest, Phillip Swanson, Yueh-Ming Loo, Joseph R. Francica, Wade Blair, Mark Esser   +28 more
doaj   +2 more sources

mRNA-Based Vaccines [PDF]

Vaccines, 2021
Increases in the world’s population and population density promote the spread of emerging pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional methods used to identify and produce new vaccines are not adequate, in most instances, to ensure global protection.
Frank Kowalzik, Daniel Schreiner, Christian Jensen, Daniel Teschner, Stephan Gehring, Fred Zepp   +5 more
openaire   +3 more sources

mRNA Vaccines against Flaviviruses [PDF]

Vaccines, 2021
Numerous vaccines have now been developed using the mRNA platform. In this approach, mRNA coding for a viral antigen is in vitro synthesized and injected into the host leading to exogenous protein expression and robust immune responses. Vaccines can be rapidly developed utilizing the mRNA platform in the face of emerging pandemics.
Clayton J. Wollner, Justin M. Richner
openaire   +3 more sources

Impact of vaccination and non-pharmacological interventions on COVID-19: a review of simulation modeling studies in Asia

Frontiers in Public Health, 2023
IntroductionEpidemiological modeling is widely used to offer insights into the COVID-19 pandemic situation in Asia. We reviewed published computational (mathematical/simulation) models conducted in Asia that assessed impacts of pharmacological and non ...
Karan Thakkar, Julia Regazzini Spinardi, Jingyan Yang, Moe H. Kyaw, Egemen Ozbilgili, Carlos Fernando Mendoza, Helen May Lin Oh   +6 more
doaj   +1 more source

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Vaccines, 2023
mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19.
Alexey D. Perenkov, Alena D. Sergeeva, Maria V. Vedunova, Dmitri V. Krysko   +3 more
doaj   +1 more source

Varicella-Zoster viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav-1.8 neuroblastoma cell line [PDF]

, 2013
Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). We undertook a heterologous infection in vitro study to determine whether PHN-associated VZV isolates ...
A Vafai, BM Bradley, C Bourdon-Wouters, C Han, D Quan, DH Gilden, DW Wareham, Edward G. Rowan, EM Garry, Esther Grinfeld, Fiona Scott, FS Hasnie, FT Scott, G Ashrafi, G. H. Ashrafi, J Fogh, J Lai, JD Markman, JN Wood, Joseph Charles Glorioso, Judith Breuer, MA Hamza, MH Meisler, MJ Craner, MJ Quinlivan, ML Szpara, N Storey, Paul Montague, Peter G. E. Kennedy, PGE Kennedy, PGE Kennedy, PGE Kennedy, PR Kinchington, R Dabby, R Mahalingam, RG Dalziel, RL Finnen, S Schünemann, SG Waxman, SJ Medhurst, SM Fleetwood-Walker, TR Cummins, W Peng, WA Catterall, X Zhou   +44 more
core   +11 more sources

Research Advances on the Stability of mRNA Vaccines

Viruses, 2023
Compared to other vaccines, the inherent properties of messenger RNA (mRNA) vaccines and their interaction with lipid nanoparticles make them considerably unstable throughout their life cycles, impacting their effectiveness and global accessibility.
Feiran Cheng, Yiping Wang, Yu Bai, Zhenglun Liang, Qunying Mao, Dong Liu, Xing Wu, Miao Xu   +7 more
doaj   +1 more source

Neo-Antigen mRNA Vaccines [PDF]

Vaccines, 2020
The interest in therapeutic cancer vaccines has caught enormous attention in recent years due to several breakthroughs in cancer research, among which the finding that successful checkpoint blockade treatments reinvigorate neo-antigen-specific T cells and that successful adoptive cell therapies are directed towards neo-antigens. Neo-antigens are cancer-
Arthur Esprit, Wout de Mey, Rajendra Bahadur Shahi, Kris Thielemans, Lorenzo Franceschini, Karine Breckpot   +5 more
openaire   +4 more sources

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Vaccines, 2022
Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here,
Eli Magen, Sumit Mukherjee, Mahua Bhattacharya, Rajesh Detroja, Eugene Merzon, Idan Blum, Alejandro Livoff, Mark Shlapobersky, Gideon Baum, Ran Talisman, Evgenia Cherniavsky, Amir Dori, Milana Frenkel-Morgenstern   +12 more
doaj   +1 more source